Plasma Fractionation Market Size, Share, Growth, and Industry Analysis, By Type (Albumin,Immune Globulin,Coagulation Factor,Others), By Application (Hospital,Retail Pharmacy,Other), Regional Insights and Forecast to 2035

•   
•   
  

  Download Free Sample to learn more about this report

    

PLASMA FRACTIONATION MARKET OVERVIEW

Global Plasma Fractionation market size, valued at USD 40.82 billion in 2026, is expected to climb to USD 77.72 billion by 2035 at a CAGR of 7.5%.

The Plasma Fractionation Market is driven by the collection and processing of human plasma into 4 primary protein therapies, including albumin, immunoglobulins, coagulation factors, and protease inhibitors. Globally, over 70 million liters of plasma are fractionated annually, with more than 60% sourced from voluntary donations. Plasma-derived therapies are used in over 100 clinical indications, including hemophilia, primary immunodeficiency, and liver diseases. More than 300 plasma fractionation centers operate worldwide, and over 40 licensed plasma-derived products are available in regulated markets. Plasma Fractionation Market Analysis shows that demand is expanding across 6 major therapeutic categories and 25+ chronic disease segments, making Plasma Fractionation Market Research Report data highly relevant for long-term healthcare planning.

In the United States, the Plasma Fractionation Market Size is the largest globally, contributing over 65% of total plasma supply. The U.S. operates more than 900 plasma collection centers, accounting for over 50 million liters of plasma annually. Approximately 70% of the world’s plasma used for fractionation originates in the U.S., supported by over 20 FDA-approved fractionation facilities. Around 3 million Americans rely on plasma-derived therapies annually, including over 30,000 hemophilia patients. Plasma donation frequency is regulated at 2 times per week, and over 38 million plasma donations are recorded annually, making the U.S. a dominant force in the Plasma Fractionation Industry Analysis and Plasma Fractionation Market Outlook.

KEY FINDINGS OF PLASMA FRACTIONATION MARKET

• Key Market Driver: Over 65% growth in plasma therapy demand linked to immunodeficiency prevalence rising by 45%, hemophilia diagnosis increasing by 30%, chronic liver disease cases expanding by 40%, autoimmune disorders growing by 35%, and plasma-derived biologics usage rising by 50% across therapeutic applications globally.

• Major Market Restraint: Approximately 55% cost burden from plasma processing, 40% regulatory compliance delays, 35% donor eligibility limitations, 30% supply chain constraints, and 25% high cold-chain logistics complexity collectively restricting Plasma Fractionation Market Growth and Plasma Fractionation Industry expansion across emerging healthcare systems.

• Emerging Trends: More than 60% adoption of recombinant-plasma hybrid therapies, 50% integration of AI-based donor screening, 45% growth in subcutaneous immunoglobulin therapies, 35% expansion of automated fractionation facilities, and 30% rise in rare disease plasma therapy pipelines shaping Plasma Fractionation Market Trends.

• Regional Leadership: North America holds nearly 55% plasma collection share, Europe maintains around 20% fractionation capacity, Asia-Pacific contributes over 15% rising supply share, Latin America contributes 6%, and Middle East & Africa accounts for approximately 4% in the global Plasma Fractionation Market Share landscape.

• Competitive Landscape: Top 5 companies control nearly 70% fractionation capacity, top 10 manufacturers hold 85% market presence, vertically integrated players manage 60% plasma collection networks, while regional manufacturers contribute 15% localized supply and contract fractionators represent about 10% industry structure.

• Market Segmentation: Immunoglobulins account for nearly 45% utilization, albumin represents 25%, coagulation factors contribute around 20%, specialty proteins make up 10%, hospitals drive 60% consumption, retail pharmacies hold 25%, and alternative channels maintain 15% application distribution globally.

• Recent Development: Over 40% expansion in plasma collection infrastructure since 2023, 35% increase in fractionation capacity investments, 30% rise in regulatory approvals for new immunoglobulin therapies, 25% increase in subcutaneous product launches, and 20% expansion in Asia-Pacific plasma networks.

Latest Trends

The Plasma Fractionation Market Trends indicate a steady shift toward high-purity biologics and advanced plasma protein therapies. Immunoglobulin therapies account for nearly 45% of plasma utilization globally, with demand rising in over 80 countries due to increasing diagnosis rates of primary immunodeficiency affecting nearly 1 in 1,200 individuals. Subcutaneous immunoglobulin therapies now represent over 30% of immunoglobulin usage, compared to 15% a decade earlier. Automated fractionation technologies have improved yield efficiency by approximately 20%, while pathogen reduction technologies reduce contamination risk by over 99.9%. Emerging economies are witnessing over 35% growth in plasma collection infrastructure, with more than 200 new collection centers added since 2023. Plasma Fractionation Market Insights also highlight rising demand for hyperimmune globulins, particularly in infectious disease outbreaks, with production volumes increasing by 25% during pandemic phases. Additionally, over 50% of fractionators are investing in digital traceability systems to ensure donor tracking across multi-step plasma supply chains.

MARKET DYNAMICS

Driver

Rising demand for plasma-derived therapies in chronic and rare diseases.

The Plasma Fractionation Market Growth is primarily driven by the rising prevalence of chronic and rare diseases requiring plasma proteins. Over 6 million people globally suffer from primary immunodeficiency disorders, with diagnosis rates increasing by 20% in the past decade. Hemophilia affects over 400,000 individuals worldwide, and nearly 75% require regular clotting factor therapies derived from plasma. Liver disease cases have exceeded 1.5 million annually in developed nations, with albumin usage growing by 35% in critical care settings. Plasma-derived therapies are used in more than 120 clinical indications, including Guillain-Barré syndrome and Kawasaki disease. With over 70 million liters of plasma processed annually, expanding therapeutic reliance continues to fuel Plasma Fractionation Market Forecast and Plasma Fractionation Market Opportunities.

Restraint

Limited plasma supply and regulatory barriers.

Plasma supply limitations remain a major restraint in the Plasma Fractionation Industry Report. Only about 2% of the global population donates plasma regularly, restricting supply expansion despite growing demand. Stringent donor eligibility criteria exclude nearly 30% of potential donors due to age, health, or travel restrictions. Regulatory approval timelines for new fractionation plants can exceed 5–7 years, delaying capacity expansion. Cold chain logistics require storage temperatures between -20°C and -40°C, increasing operational complexity by 25%. Additionally, over 40 countries restrict paid plasma donation, reducing plasma collection volumes by up to 50% compared to compensated systems. These factors collectively constrain Plasma Fractionation Market Share growth in developing regions.

Expansion of plasma collection networks in emerging markets

Opportunity

Emerging economies present strong Plasma Fractionation Market Opportunities due to increasing healthcare access and infrastructure investments. Asia-Pacific plasma collection volumes have grown by over 35% since 2020, supported by rising healthcare spending and improved diagnostic rates. China alone has added more than 100 new plasma collection centers in 5 years, increasing domestic fractionation capacity by 30%.

India and Southeast Asia are expanding immunoglobulin access programs, targeting over 50 million underserved patients. Local manufacturing initiatives are reducing import dependence by nearly 20%, while public-private partnerships have accelerated fractionation plant approvals by 25%. These developments are reshaping Plasma Fractionation Market Outlook in high-growth healthcare economies.

High processing complexity and manufacturing costs

Challenge

The plasma fractionation process involves over 10 sequential purification steps, including cryoprecipitation, chromatography, and viral inactivation, making it highly complex. Fractionation yields can vary by 15–20% depending on plasma quality and process efficiency. Manufacturing facilities require investments exceeding hundreds of millions in infrastructure and biosafety compliance, with operational costs 30% higher than traditional biologics production.

Quality control testing involves more than 1,000 assays per batch, extending production cycles up to 12 months. Additionally, plasma wastage during fractionation can reach 10%, impacting overall supply efficiency. These operational challenges remain key barriers highlighted in Plasma Fractionation Market Research Report evaluations.

•   
•   
  

  Download Free Sample to learn more about this report

    

PLASMA FRACTIONATION MARKET SEGMENTATION

By Type

• Albumin: Albumin represents approximately 25% of plasma fractionation output globally, with annual usage exceeding 500 metric tons. It is widely used in critical care, burns, trauma, and liver cirrhosis management, with over 60% of albumin consumption occurring in intensive care units. China accounts for nearly 40% of global albumin demand due to high hospitalization rates. Albumin solutions are typically available in 5% and 20% concentrations, with usage expanding by 30% in sepsis treatment protocols. Plasma Fractionation Market Insights show that albumin demand is rising in developing regions where critical care admissions have increased by 20% over the past decade.

• Immune Globulin: Immune globulins dominate with nearly 45% market share in plasma protein utilization. Global immunoglobulin consumption exceeds 200 tons annually, with over 70% used in treating primary and secondary immunodeficiency disorders. Subcutaneous immunoglobulin therapies now represent 30% of total immunoglobulin use, enabling home-based treatment for over 1 million patients. The U.S. accounts for nearly 50% of immunoglobulin consumption, driven by advanced diagnosis and reimbursement coverage. Plasma Fractionation Market Analysis indicates rising use in neurological disorders, with immunoglobulin therapy usage increasing by 25% in conditions like CIDP and myasthenia gravis.

• Coagulation Factor: Coagulation factors account for nearly 20% of plasma fractionation output, primarily used for hemophilia A and B treatment affecting over 400,000 individuals globally. Plasma-derived factor VIII and IX therapies are widely used in regions where recombinant alternatives remain limited. Around 60% of hemophilia patients in developing countries still rely on plasma-derived factors. Cryoprecipitate remains a critical component in trauma care, with over 2 million transfusions annually. Plasma Fractionation Market Forecast data suggests steady demand as plasma-derived clotting factors remain essential in emergency bleeding management.

• Others: Other plasma proteins, including alpha-1 antitrypsin and fibrinogen concentrates, represent approximately 10% of fractionation output. Alpha-1 antitrypsin therapy is used in over 100,000 patients globally for genetic deficiency disorders. Fibrin sealants derived from plasma are used in over 5 million surgical procedures annually, particularly in cardiovascular and orthopedic surgeries. Specialty proteins are also gaining traction in rare disease treatment, with clinical pipelines expanding by 20% in the past 5 years. Plasma Fractionation Industry Analysis shows rising diversification into niche plasma-derived therapeutics.

By Application

• Hospital: Hospitals account for nearly 60% of plasma-derived therapy utilization, driven by intensive care, trauma, and surgical applications. Over 70% of albumin and 65% of coagulation factors are administered in hospital settings. Globally, more than 50 million hospital admissions annually involve plasma protein therapy. Intensive care units consume nearly 40% of hospital plasma usage, particularly in sepsis and liver failure cases. Plasma Fractionation Market Share remains highest in tertiary care hospitals with advanced transfusion facilities.

• Retail Pharmacy: Retail pharmacies represent approximately 25% of distribution, primarily for long-term immunoglobulin therapies and home infusion programs. Over 1.5 million patients receive outpatient immunoglobulin therapy annually, with retail channels supporting recurring prescriptions. Subcutaneous immunoglobulin therapies have increased pharmacy distribution by 35% in the past decade. Specialty pharmacy networks in North America and Europe dominate this segment, ensuring cold-chain compliance across over 10,000 distribution points.

• Other: Other applications, including specialty clinics and homecare settings, account for nearly 15% of plasma-derived therapy usage. Home-based infusion programs have grown by 40% in developed markets, particularly for immunoglobulin therapies. Specialty clinics manage rare disease treatments for over 500,000 patients globally. Plasma Fractionation Market Outlook highlights increasing adoption of decentralized care models supported by portable infusion devices and digital monitoring systems.

•   
•   
  Download Free Sample to learn more about this report

    

PLASMA FRACTIONATION MARKET REGIONAL OUTLOOK

• North America

North America dominates the Plasma Fractionation Market Share with over 55% of global plasma supply and nearly 60% of total fractionation capacity. The United States leads the region with more than 900 plasma collection centers and over 50 million liters of plasma collected annually, representing nearly 70% of global plasma sourcing. Canada contributes an additional 1–2 million liters yearly through national blood systems and growing private plasma initiatives. Immunoglobulin consumption in North America exceeds 100 tons annually, driven by high diagnosis rates of primary immunodeficiency affecting nearly 1 in 1,200 individuals. Hospitals account for more than 65% of plasma therapy usage in the region, particularly in intensive care and neurology. Over 40% of global fractionation facilities are located in North America, with more than 20 FDA-licensed plants operating under strict compliance standards. Retail pharmacy distribution channels manage approximately 30% of outpatient immunoglobulin therapies. Investments in digital donor screening have increased collection efficiency by nearly 15% since 2023. North America also leads in R&D, with over 50 ongoing clinical trials involving plasma-derived therapies targeting rare diseases and autoimmune disorders, reinforcing its leadership in the Plasma Fractionation Market Outlook.

• Europe

Europe holds approximately 20% share in the Plasma Fractionation Market Size and is characterized by strong regulatory harmonization and voluntary donation systems. The region operates over 250 plasma collection centers and processes nearly 15 million liters of plasma annually. Germany, Austria, and Hungary contribute significantly to plasma sourcing, while Switzerland and Spain host major fractionation facilities. Over 80% of plasma donations in Europe come from voluntary non-remunerated donors, influencing supply availability but ensuring ethical sourcing standards. The region has more than 30 licensed fractionation plants supplying therapies to over 500 million residents. Immunoglobulin utilization has increased by nearly 25% over the last decade, especially in neurological indications such as chronic inflammatory demyelinating polyneuropathy. Albumin consumption exceeds 100 tons annually across European healthcare systems, particularly in liver disease management. Regulatory approvals for plasma-derived therapies typically require 3–5 years, slightly longer than North America. Cross-border plasma exchange programs supply over 10% of intra-regional demand. Europe is also advancing plasma self-sufficiency initiatives targeting a 20% increase in domestic collection by 2030, strengthening its Plasma Fractionation Industry Analysis profile.

• Asia-Pacific

Asia-Pacific accounts for over 15% of the Plasma Fractionation Market Share and is the fastest-expanding region due to increasing healthcare demand and infrastructure investments. China leads with more than 300 licensed plasma collection stations and over 10 domestic fractionation companies processing nearly 10–12 million liters of plasma annually. The country meets approximately 70% of its domestic plasma therapy demand locally, supported by government-controlled donation programs. Japan contributes around 2 million liters annually and maintains advanced fractionation technologies with high purity standards. South Korea and Australia together add nearly 1 million liters of fractionation capacity. India is emerging rapidly with over 50 licensed blood banks involved in plasma programs, though domestic fractionation capacity remains limited. Plasma therapy demand in Asia-Pacific has increased by nearly 30% due to rising chronic disease prevalence and improved diagnostics. Immunoglobulin usage has grown by 35% over the past decade, particularly in urban healthcare centers. Governments across the region are investing in plasma self-reliance strategies, with over 15 new fractionation facilities proposed between 2023 and 2025. Import dependency has declined by approximately 20% in key markets, reflecting growing regional strength in the Plasma Fractionation Market Forecast.

• Middle East & Africa

The Middle East & Africa region represents around 4% of the Plasma Fractionation Market Outlook but shows rising demand due to healthcare modernization. Saudi Arabia and the UAE collectively conduct over 500,000 plasma donations annually through national blood programs, while South Africa processes nearly 500,000 liters via established blood services. Most countries in the region still rely on imports for over 70% of plasma-derived therapies, highlighting a significant supply gap. Immunoglobulin demand has increased by nearly 20% as diagnostic capabilities improve across tertiary care centers. Albumin usage is growing by approximately 15% annually in critical care settings, particularly in liver disease and trauma cases. Governments in at least 5 countries have announced plasma self-sufficiency plans, including new fractionation plants designed to process over 200,000 liters annually each. Regional healthcare spending growth has led to a 25% increase in plasma therapy adoption since 2022. Limited donor awareness remains a barrier, with less than 1% of the eligible population donating plasma regularly. Despite these challenges, infrastructure investments and partnerships with global fractionators are expected to enhance local capabilities, strengthening long-term Plasma Fractionation Market Opportunities across the region.

LIST OF TOP PLASMA FRACTIONATION COMPANIES

• Takeda
• CSL
• Grifols
• Octapharma
• Kedrion
• LFB Group
• Biotest
• BPL
• RAAS
• CBPO
• Hualan Bio
• Tiantan Bio
• Shuanglin Bio
• Boya Bio
• Yuanda Shuyang
• Weiguang Bio
• Nanyue Bio
• KM Biologics

Top Two Companies By Market Share:

• CSL: CSL holds approximately 30% of global plasma fractionation capacity, supported by over 300 plasma collection centers and distribution across more than 100 countries, making it the largest player in the Plasma Fractionation Market Share landscape.
• Takeda: Takeda accounts for nearly 25% global share, driven by large-scale fractionation facilities across 4 continents and an integrated plasma network handling millions of liters annually, positioning it as the second-largest leader in the Plasma Fractionation Industry Analysis.

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment in the Plasma Fractionation Market has intensified with over 40 new plasma centers established globally between 2023 and 2025. Fractionation facility expansions have increased processing capacity by nearly 35%, with manufacturers investing in high-throughput chromatography systems improving yields by 15%. North America accounts for over 50% of ongoing plasma infrastructure investments, while Asia-Pacific represents nearly 30% of new projects. Governments in 10+ countries are funding plasma self-sufficiency initiatives, aiming to reduce import reliance by up to 25%. Public-private partnerships have accelerated regulatory approvals by approximately 20%, enabling faster capacity deployment. Emerging markets are attracting over 15 new fractionation plant proposals, each targeting annual processing volumes exceeding 500,000 liters. Plasma Fractionation Market Opportunities are also driven by rare disease therapy pipelines, with over 50 plasma-derived products in clinical development globally.

NEW PRODUCT DEVELOPMENT

New product development in the Plasma Fractionation Market is focused on higher purity and patient-friendly delivery formats. Subcutaneous immunoglobulin products have increased by over 30% in the past 5 years, allowing self-administration for over 1 million patients globally. Extended half-life coagulation factors have improved dosing intervals by nearly 40%, reducing infusion frequency. Hyperimmune globulins targeting infectious diseases have seen development expansion by 25%, especially in pandemic preparedness programs. Manufacturers are developing recombinant-plasma hybrid therapies with 20% improved bioavailability. Liquid-stable albumin formulations with extended shelf life of up to 36 months are entering new markets. Plasma-derived fibrin sealants are also evolving, with new surgical adhesives used in over 2 million procedures annually. Plasma Fractionation Market Trends highlight increasing R&D spending focused on personalized plasma therapies and rare disease biologics.

FIVE RECENT DEVELOPMENTS (2023–2025)

• A major manufacturer expanded plasma collection capacity by 25% through 50 new centers across North America in 2024.
• A global plasma leader increased fractionation output by 20% after commissioning a new plant processing over 1 million liters annually in 2023.
• A European fractionator launched a new subcutaneous immunoglobulin therapy improving patient compliance by 30% in 2025.
• An Asia-based company increased domestic plasma sourcing by 35% through government-backed donation campaigns in 2024.
• A multinational plasma producer invested in pathogen reduction technology improving viral safety margins by 99.9% across product lines in 2023.

PLASMA FRACTIONATION MARKET REPORT COVERAGE

The Plasma Fractionation Market Research Report provides detailed insights across more than 20 countries and 4 major regions, analyzing over 70 million liters of plasma processed annually. The report evaluates more than 30 fractionation facilities and profiles over 18 major manufacturers operating across global supply chains. It covers segmentation across 4 major product categories and 3 application channels, analyzing utilization patterns across 100+ clinical indications. The study includes plasma collection trends, donor demographics, and fractionation technology adoption rates exceeding 50% automation in leading facilities. Plasma Fractionation Industry Report coverage also includes regulatory frameworks across 25 jurisdictions and evaluates over 50 pipeline therapies in development. The analysis integrates supply-demand mapping across more than 200 plasma collection networks, offering comprehensive Plasma Fractionation Market Insights for stakeholders targeting long-term expansion and strategic planning.